Published
13 minute read
If you're seeing more hair in the shower, noticing that your ponytail feels thinner, or watching your part gradually widen, the first question is usually simple:
The answer matters because female hair loss is not one diagnosis.
Some women have female pattern hair loss, where follicles gradually become smaller and produce finer hairs. Others are experiencing temporary shedding after pregnancy, illness, weight loss or another physical stress. Menopause can uncover or accelerate several different types of hair loss. Iron deficiency, thyroid disease and other medical problems can contribute as well. [1]
That is why I don't start by recommending a supplement, medication or procedure.
I start by trying to determine why you're losing hair.
Once we understand that, the treatment becomes much clearer.
Female pattern hair loss is the most common form of progressive hair thinning in women.
Unlike the classic receding hairline we often see in men, women more commonly notice a widening central part and reduced density across the top of the scalp, while the frontal hairline may remain relatively preserved. [1]
The underlying process involves miniaturization.
A healthy follicle that once produced a thick terminal hair gradually begins producing a finer, shorter hair. Over time, enough follicles can miniaturize that the scalp becomes increasingly visible.
Female pattern hair loss becomes more common with age, but it is not limited to older women. [1]
The important point is that this is generally a progressive condition.
If we recognize it early, our goal is not simply to regrow hair. It is also to protect the follicles you still have.
It may be contributing, but “menopause hair loss” isn't a single diagnosis.
During perimenopause and menopause, hormone levels change substantially. Hair follicles are hormonally responsive, and these changes can affect both hair growth and hair calibre. Female pattern hair loss also becomes increasingly common during this period. [2]
Some women notice gradual thinning across the top of the scalp.
Others notice more diffuse shedding.
And occasionally menopause happens at the same time as something completely separate, such as thyroid disease, iron deficiency or a scarring form of alopecia.
That distinction matters.
I don't want to tell someone, “It's menopause,” and miss another treatable problem.
Postpartum hair loss is different.
During pregnancy, hormonal changes keep a larger proportion of your hair in the active growth phase. After delivery, many of those hairs move into the resting and shedding phases at roughly the same time.
The result is telogen effluvium, a temporary period of diffuse shedding that often begins a few months after childbirth. Most women gradually move back toward their previous density over time. [3]
In many cases, the correct treatment is reassurance and patience.
But postpartum shedding can sometimes unmask hair loss that was already developing, particularly female pattern hair loss. A study of women with postpartum shedding found that a substantial proportion also had evidence of another underlying hair-loss disorder. [4]
So if shedding is unusually severe, persists longer than expected, or your density does not recover, it is worth looking more closely.
Sometimes.
I don't believe every woman with hair thinning needs an enormous panel of laboratory tests.
If your examination is typical for female pattern hair loss and your history doesn't suggest another problem, extensive testing may add very little.
But if the history or pattern raises the possibility of another cause, bloodwork can be important.
Depending on the patient, I may consider testing such as:
Canadian recommendations particularly emphasize careful history, examination and targeted bloodwork such as CBC, TSH and ferritin when assessing women with androgenetic hair loss. [5]
The principle is simple:
Don't treat the hair while ignoring the reason it may be falling out.
Only when there is a reason.
The hair-supplement industry is enormous, and women with thinning hair are frequently told to take biotin, iron, zinc, vitamin D or increasingly elaborate combinations of supplements.
But more is not necessarily better.
If bloodwork shows iron deficiency, replacing iron makes sense.
If you are vitamin D deficient, treating that deficiency is reasonable.
If dietary intake is inadequate, correcting protein or another nutritional deficiency matters.
What I don't recommend is assuming that every case of female hair loss is caused by a vitamin deficiency and treating it blindly with supplements.
In particular, taking high-dose biotin simply because your hair is thinning has limited rationale if you are not deficient, and high doses can interfere with certain laboratory tests.
Supplements should correct a deficiency. They should not replace a diagnosis.
For many women with female pattern hair loss, minoxidil remains the foundation of treatment.
Topical minoxidil is a first-line option in current recommendations. It can help prolong the hair-growth phase, improve density and slow progression, but results take time. Six to twelve months is a more realistic time frame for judging response than six weeks. [1,5]
Some women cannot tolerate topical treatment or prefer another option. Low-dose oral minoxidil is increasingly used off-label in selected patients, although it requires medical assessment because it can affect blood pressure and may cause fluid retention or unwanted facial or body hair.
Depending on the patient, I may also discuss anti-androgen treatment.
Spironolactone can be useful for selected women, particularly when androgen sensitivity is thought to be contributing. Recent randomized data support an additive effect when spironolactone is combined with topical minoxidil, although menstrual irregularities and other side effects need to be considered. [6]
Finasteride or dutasteride may have a role in selected women, particularly after menopause, but reproductive status matters because these medications can harm a developing male fetus. Canadian consensus recommendations therefore treat pre- and post-menopausal women differently. [5]
There isn't one “female hair-loss pill.”
The medication should fit the diagnosis, medical history and stage of life.
At FORM, another option we can incorporate into a hair-restoration program is Alma TED.
TED stands for trans-epidermal delivery.
The device uses low-frequency ultrasound together with acoustic pressure to increase scalp permeability and enhance delivery of a topical formulation without needles. [7]
The standard published Alma TED protocol has used a peptide-based topical hair-care formulation.
For patients, the attraction is straightforward: the treatment is non-invasive and does not require injections or significant downtime.
But I think the evidence needs to be presented honestly.
There are encouraging early data using Alma TED with its standard topical formulation, but the evidence base is much smaller than the evidence supporting established treatments such as minoxidil.
So I don't view TED as a replacement for diagnosis.
I view it as an adjunct.
If a patient has iron deficiency, TED isn't the treatment for iron deficiency.
If she has untreated female pattern hair loss, I don't want a device to distract us from discussing medical treatment.
The technology can be incorporated into a broader plan when appropriate, but the plan still has to address the cause.
Platelet-rich plasma, or PRP, is another procedure commonly used for pattern hair loss, and systematic reviews suggest that it can improve hair density in some patients. [8,9]
The challenge is that PRP is not one standardized treatment.
PRP is prepared from the patient's own blood, so the biological composition of the final product can vary from patient to patient. Preparation systems also differ in platelet concentration, leukocyte content, activation methods and processing protocols. One systematic review found considerable inconsistency in how PRP was prepared and even how its final composition was reported across hair-loss studies. [8]
Delivery introduces another variable. PRP requires repeated injections across the scalp, and treatment protocols vary in injection depth, spacing, volume and treatment frequency. These differences in the patient's plasma, preparation method and delivery technique are likely among the reasons results have varied across the literature, even though meta-analyses overall suggest a potential benefit for androgenetic hair loss. [8,9]
At FORM, I generally use Alma TED in lieu of PRP when I want to add a procedure-based treatment to a hair-restoration program.
TED removes some important sources of variability. It does not depend on the composition of an individual patient's plasma, it avoids repeated scalp injections, and it allows us to use a defined topical formulation with a device-based delivery protocol.
That does not mean the evidence proves TED is superior to PRP. We do not have strong enough head-to-head data to make that claim.
Rather, I favour TED because it gives us a non-invasive and more reproducible delivery platform that can be incorporated into a broader treatment plan while we continue to address the underlying cause of the hair loss.
At FORM, we may also discuss using the Alma TED delivery platform with a secretome-based topical formulation instead of the standard peptide-based TED serum.
This is a different strategy, and I think it is important to describe it accurately.
A secretome is the collection of biologically active substances released by cells. Depending on how a product is produced, this can include growth factors, signalling proteins, cytokines and extracellular vesicles. Secretomes are not the same thing as transplanting stem cells, and the terms “secretome” and “exosome” should not automatically be used interchangeably.
Why is there interest in them?
Laboratory and early clinical research suggests that cell-derived secretomes and extracellular vesicles may influence signalling pathways involved in follicle growth, dermal papilla activity and the hair-growth cycle. Recent systematic reviews describe promising signals for hair regeneration, including androgenetic alopecia. [10]
But this is where I separate interesting biology from established treatment.
Secretome preparations are not standardized. They can differ according to:
The published clinical literature remains much smaller and less standardized than it is for treatments such as minoxidil.
I view this treatment protocol as an emerging adjunct, not the foundation of the patient's hair-loss treatment.
The foundation is still diagnosis.
Then we correct deficiencies when they exist, control progressive hair loss where possible, and add treatments such as TED when they fit the overall strategy.
Sudden diffuse shedding is different from slowly progressive female pattern loss.
A condition called telogen effluvium can occur several months after a trigger such as:
In these situations, treating the trigger may matter more than immediately reaching for a hair-growth procedure.
The encouraging part is that acute telogen effluvium is often temporary.
The harder part is making sure that is actually the diagnosis.
There are some situations where I want a closer medical or dermatologic assessment.
These include:
Some scarring forms of hair loss can cause permanent follicle destruction, so these shouldn't simply be treated as ordinary female pattern thinning. [1]
Start with the diagnosis.
At FORM Face + Body in Toronto, my approach to female hair loss is usually:
First, determine the pattern.
Is this progressive miniaturization, temporary shedding or something else?
Second, look for reversible contributors.
If the history suggests iron deficiency, thyroid disease, nutritional deficiency or another medical issue, we investigate it.
Third, protect the hair you still have.
That may mean minoxidil, an anti-androgen or another medically appropriate treatment.
Fourth, consider adjunctive treatments.
Depending on the patient, that may include Alma TED with its standard topical formulation or, in selected circumstances, a secretome-based topical delivered using TED. The evidence supporting secretomes remains emerging, so I discuss that distinction with patients rather than presenting it as established therapy.
There is no single treatment for “women's hair loss” because there is no single cause.
And that is the most important point.
Don't start with the supplement. Don't start with the device. Don't start with the secretome. Start by finding out why your hair is thinning.
Once we know that, we can build a treatment plan that actually addresses the problem.
A medical assessment is required to determine the cause of hair loss and which treatments are appropriate. Prescription medications may have important risks, contraindications and pregnancy considerations. Emerging therapies such as secretome-based products have a more limited evidence base and should be considered individually. This article is educational and is not a substitute for individual medical advice.
References
